Reviewing the current classification of inhibitor of growth family proteins

Cancer Science

Volumn 100, Issue 7, 2009, Pages 1173-1179

  Unoki, Motoko ^a,c   Kumamoto, Kensuke ^b,c   Takenoshita, Seiichi ^b   Harris, Curtis C ^c  

^a INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE METHYLTRANSFERASE; INHIBITOR OF GROWTH PROTEIN; INHIBITOR OF GROWTH PROTEIN 1; INHIBITOR OF GROWTH PROTEIN 2; INHIBITOR OF GROWTH PROTEIN 3; INHIBITOR OF GROWTH PROTEIN 4; INHIBITOR OF GROWTH PROTEIN 5; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL AGING; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CLASSIFICATION; COLORECTAL CANCER; DNA HISTONE INTERACTION; DNA REPLICATION; FIBROBLAST; GENE OVEREXPRESSION; GENE STRUCTURE; HUMAN; KNOCKOUT MOUSE; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW;

ANIMALS; DNA REPLICATION; HUMANS; MICE; MODELS, BIOLOGICAL; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 67449088207     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01183.x     Document Type: Review

References (78)

1. Soliman MA, Riabowol K. After a decade of study-ING, a PHD for a versatile family of proteins. Trends Biochem Sci 2007; 32: 509-19.
2. Doyon Y, Cayrou C, Ullah M et al. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell 2006; 21: 51-64.
3. Kumamoto K, Spillare EA, Fujita K et al. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 2008; 68: 3193-203.
4. Unoki M, Kumamoto K, Robles AI et al. A novel ING2 isoform, ING2b, synergizes with ING2a to prevent cell cycle arrest and apoptosis. FEBS Lett 2008; 582: 3868-74.
5. Coles AH, Liang H, Zhu Z et al. Deletion of p37Ing1 in mice reveals a p53-independent role for Ing1 in the suppression of cell proliferation, apoptosis, and tumorigenesis. Cancer Res 2007;67: 2054-61.
6. Kichina JV, Zeremski M, Aris L et al. Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas. Oncogene 2006; 25: 857-66.
7. Kumamoto K, Fujita K, Kurotani R et al. ING2 is up-regulated in colon cancer and increases invasion by enhanced MMP13 expression. Int J Can 2009; in press.
8. Unoki M, Kumamoto K, Harris CC. ING proteins as potential anticancer drug targets. Curr Drug Targets 2009; in press.
9. Skowyra D, Zeremski M, Neznanov N et al. Differential association of products of alternative transcripts of the candidate tumor suppressor ING1 with the mSin3/HDAC1 transcriptional corepressor complex. J Biol Chem 2001; 276: 8734-9.
10. Kuzmichev A, Zhang Y, Erdjument-Bromage H, Tempst P, Reinberg D. Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppressor p33 (ING1). Mol Cell Biol 2002; 22: 835-48.
11. Vieyra D, Loewith R, Scott M et al. Human ING1 proteins differentially regulate histone acetylation. J Biol Chem 2002; 277: 29 832-9.
12. Pena PV, Davrazou F, Shi X et al. Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2. Nature 2006; 442: 100-3.
13. Pena PV, Hom RA, Hung T et al. Histone H3K4me3 binding is required for the DNA repair and apoptotic activities of ING1 tumor suppressor. J Mol Biol 2008; 380: 303-12.
14. Shi X, Hong T, Walter KL et al. ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature 2006; 442: 96-9.
15. Palacios A, Garcia P, Padro D et al. Solution structure and NMR characterization of the binding to methylated histone tails of the plant homeodomain finger of the tumour suppressor ING4. FEBS Lett 2006; 580: 6903-8.
16. Palacios A, Munoz IG, Pantoja-Uceda D et al. Molecular basis of histone H3K4me3 recognition by ING4. J Biol Chem 2008; 283: 15 956-64.
17. Unoki M, Shen JC, Zheng ZM, Harris CC. Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility. J Biol Chem 2006; 281: 34 677-86.
18. Raho G, Miranda C, Tamborini E, Pierotti MA, Greco A. Detection of novel mRNA splice variants of human ING4 tumor suppressor gene. Oncogene 2007; 26: 5247-57.
19. Tsai KW, Lin WC. Quantitative analysis of wobble splicing indicates that it is not tissue specific. Genomics 2006; 88: 855-64.
20. Tsai KW, Tseng HC, Lin WC. Two wobble-splicing events affect ING4 protein subnuclear localization and degradation. Exp Cell Res 2008; 314: 3130-41.
21. Saito A, Furukawa T, Fukushige S et al. p24/ING1-ALT1 and p47/ING1-ALT2, distinct alternative transcripts of p33/ING1. J Hum Genet 2000; 45: 177-81.
22. Zeremski M, Hill JE, Kwek SS et al. Structure and regulation of the mouse ing1 gene. Three alternative transcripts encode two phd finger proteins that have opposite effects on p53 function. J Biol Chem 1999; 274: 32 172-81.
23. Gunduz M, Ouchida M, Fukushima K et al. Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. Cancer Res 2000; 60: 3143-6.
24. Garkavtsev I, Kazarov A, Gudkov A, Riabowol K. Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat Genet 1996; 14: 415-20.
25. Garkavtsev I, Grigorian IA, Ossovskaya VS et al. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature 1998; 391: 295-8.
26. Helbing CC, Veillette C, Riabowol K, Johnston RN, Garkavtsev I. A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Cancer Res 1997; 57: 1255-8.
27. Shinoura N, Muramatsu Y, Nishimura M et al. Adenovirus-mediated transfer of p33ING1 with p53 drastically augments apoptosis in gliomas. Cancer Res 1999; 59: 5521-8.
28. Scott M, Bonnefin P, Vieyra D et al. UV-induced binding of ING1 to PCNA regulates the induction of apoptosis. J Cell Sci 2001; 114: 3455-62.
29. Soliman MA, Berardi P, Pastyryeva S et al. ING1a expression increases during replicative senescence and induces a senescent phenotype. Aging Cell 2008; 7: 783-94.
30. Jager D, Stockert E, Scanlan MJ et al. Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene. Cancer Res 1999; 59: 6197-204.
31. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003; 100: 8621-3.
32. Ythier D, Larrieu D, Brambilla C, Brambilla E, Pedeux R. The new tumor suppressor genes ING: Genomic structure and status in cancer. Int J Cancer 2008; 123: 1483-90.
33. Sanchez-Carbayo M, Socci ND, Lozano JJ et al. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 2003; 163: 505-16.
34. Soussi T. The p53 tumor suppressor gene: From molecular biology to clinical investigation. Ann N Y Acad Sci 2000; 910: 121-37.
35. Feng X, Hara Y, Riabowol K. Different HATS of the ING1 gene family. Trends Cell Biol 2002; 12: 532-8.
36. Xin H, Yoon HG, Singh PB, Wong J, Qin J. Components of a pathway maintaining histone modification and heterochromatin protein 1 binding at the pericentric heterochromatin in mammalian cells. J Biol Chem 2004; 279: 9539-46.
37. Koch CM, Andrews RM, Flicek P et al. The landscape of histone modifications across 1% of the human genome in five human cell lines. Genome Res 2007; 17: 691-707.
38. Han X, Feng X, Rattner JB et al. Tethering by lamin A stabilizes and targets the ING1 tumour suppressor. Nat Cell Biol 2008; 10: 1330-40.
39. Shimada Y, Saito A, Suzuki M, Takahashi E, Horie M. Cloning of a novel gene (ING1L) homologous to ING1, a candidate tumor suppressor. Cytogenet Cell Genet 1998; 83: 232-5.
40. Nagashima M, Shiseki M, Miura K et al. DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc Natl Acad Sci USA 2001; 98: 9671-6.
41. Lu F, Dai DL, Martinka M, Ho V, Li G. Nuclear ING2 expression is reduced in human cutaneous melanomas. Br J Cancer 2006; 95: 80-6.
42. Borkosky SS, Gunduz M, Nagatsuka H et al. Frequent deletion of ING2 locus at 4q35.1 associates with advanced tumor stage in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 2008; 135: 703-13.
43. Okano T, Gemma A, Hosoya Y et al. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer. Oncol Rep 2006; 15: 545-9.
44. Zhang HK, Pan K, Wang H et al. Decreased expression of ING2 gene and its clinicopathological significance in hepatocellular carcinoma. Cancer Lett 2008; 261: 183-92.
45. Sarker KP, Kataoka H, Chan A et al. ING2 as a novel mediator of transforming growth factor-beta-dependent responses in epithelial cells. J Biol Chem 2008; 283: 13 269-79.
46. Leeman MF, Curran S, Murray GI. The structure, regulation, and function of human matrix metalloproteinase-13. Crit Rev Biochem Mol Biol 2002; 37: 149-66.
47. Binda O, Nassif C, Branton PE. SIRT1 negatively regulates HDAC1-dependent transcriptional repression by the RBP1 family of proteins. Oncogene 2008; 27: 3384-92.
48. Wang Y, Wang J, Li G. Leucine zipper-like domain is required for tumor suppressor ING2-mediated nucleotide excision repair and apoptosis. FEBS Lett 2006; 580: 3787-93.
49. Pedeux R, Sengupta S, Shen JC et al. ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation. Mol Cell Biol 2005; 25: 6639-48.
50. Lai A, Kennedy BK, Barbie DA et al. RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of retinoblastoma tumor suppressor family proteins found in limited discrete regions of the nucleus at growth arrest. Mol Cell Biol 2001; 21: 2918-32.
51. Goeman F, Otto K, Kyrylenko S, Schmidt O, Baniahmad A. ING2 recruits histone methyltransferase activity with methylation site specificity distinct from histone H3 lysines 4 and 9. Biochim Biophys Acta 2008; 1783: 1673-80.
52. Gozani O, Karuman P, Jones DR et al. The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell 2003; 114: 99-111.
53. Nagashima M, Shiseki M, Pedeux RM et al. A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene 2003; 22: 343-50.
54. Gunduz M, Ouchida M, Fukushima K et al. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene 2002; 21: 4462-70.
55. Gunduz M, Beder LB, Gunduz E et al. Downregulation of ING3 mRNA expression predicts poor prognosis in head and neck cancer. Cancer Sci 2008; 99: 531-8.
56. Wang Y, Dai DL, Martinka M, Li G. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma. Clin Cancer Res 2007;13: 4111-16.
57. He GH, Helbing CC, Wagner MJ, Sensen CW, Riabowol K. Phylogenetic analysis of the ING family of PHD finger proteins. Mol Biol Evol 2005; 22: 104-16.
58. Wang Y, Li G. ING3 promotes UV-induced apoptosis via Fas/caspase-8 pathway in melanoma cells. J Biol Chem 2006; 281: 11 887-93.
59. Doyon Y, Selleck W, Lane WS, Tan S, Cote J. Structural and functional conservation of the NuA4 histone acetyltransferase complex from yeast to humans. Mol Cell Biol 2004; 24: 1884-96.
60. Shiseki M, Nagashima M, Pedeux RM et al. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res 2003; 63: 2373-8.
61. Hiller M, Huse K, Szafranski K et al. Widespread occurrence of alternative splicing at NAGNAG acceptors contributes to proteome plasticity. Nat Genet 2004; 36: 1255-7.
62. Tadokoro K, Yamazaki-Inoue M, Tachibana M et al. Frequent occurrence of protein isoforms with or without a single amino acid residue by subtle alternative splicing: The case of Gln in DRPLA affects subcellular localization of the products. J Hum Genet 2005; 50: 382-94.
63. Hiller M, Huse K, Szafranski K et al. Single-nucleotide polymorphisms in NAGNAG acceptors are highly predictive for variations of alternative splicing. Am J Hum Genet 2006; 78: 291-302.
64. Zhang X, Wang KS, Wang ZQ et al. Nuclear localization signal of ING4 plays a key role in its binding to p53. Biochem Biophys Res Commun 2005; 331: 1032-8.
65. Garkavtsev I, Kozin SV, Chernova O et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004; 428: 328-32.
66. Shen JC, Unoki M, Ythier D et al. Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res 2007; 67: 2552-8.
67. Ozer A, Wu LC, Bruick RK. The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). Proc Natl Acad Sci USA 2005; 102: 7481-6.
68. Kim S. HuntING4 new tumor suppressors. Cell Cycle 2005; 4: 516-17.
69. Ozer A, Bruick RK. Regulation of HIF by prolyl hydroxylases: Recruitment of the candidate tumor suppressor protein ING4. Cell Cycle 2005; 4: 1153-6.
70. Liu E, Wu J, Cao W et al. Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J Neurooncol 2007; 85: 263-70.
71. Zhang X, Xu LS, Wang ZQ et al. ING4 induces G2/M cell cycle arrest and enhances the chemosensitivity to DNA-damage agents in HepG2 cells. FEBS Lett 2004; 570: 7-12.
72. Nozell S, Laver T, Moseley D et al. The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes. Mol Cell Biol 2008; 28: 6632-45.
73. Champagne KS, Saksouk N, Pena PV et al. The crystal structure of the ING5 PHD finger in complex with an H3K4me3 histone peptide. Proteins 2008; 72: 1371-6.
74. Cheung KJ Jr, Mitchell D, Lin P, Li G. The tumor suppressor candidate p33 (ING1) mediates repair of UV-damaged DNA. Cancer Res 2001; 61: 4974-7.
75. Kataoka H, Bonnefin P, Vieyra D et al. ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res 2003; 63: 5785-92.
76. Simpson F, Lammerts van Bueren K, Butterfield N et al. The PCNA-associated factor KIAA0101/p15 (PAF) binds the potential tumor suppressor product p33ING1b. Exp Cell Res 2006; 312: 73-85.
77. Gong W, Russell M, Suzuki K, Riabowol K. Subcellular targeting of p33ING1b by phosphorylation-dependent 14-3-3 binding regulates p21WAF1 expression. Mol Cell Biol 2006; 26: 2947-54.
78. Gonzalez L, Freije JM, Cal S et al. A functional link between the tumour suppressors ARF and p33ING1. Oncogene 2006; 25: 5173-9.